CDC14B

Across TCGA pan-cancer cohorts, CDC14B Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CDC14B data layer compared with 23 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher CDC14B Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated CDC14B expression acts as an unfavorable survival marker, although some lineages such as UCEC and STAD show a favorable association.

UCEC, STAD, and MESO are the cancer types where CDC14B Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	All	0.965	0.623	.010	32	view →
STAD	DFS	Median	All	1.000	0.336	.019	28	view →
MESO	OS	Median	All	0.130	0.557	.019	18	view →
LGG	OS	Median	All	0.134	0.799	<.001	6	view →
LUSC	OS	Median	II,III,IV	0.222	0.615	.034	6	view →
ESCA	DFS	Median	All	1.000	0.306	.037	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CDC14B–UCEC (DFS)

Open the UCEC breakdown →